A 10-member panel, led by FDA Commissioner Marty Makary, recently discussed the use of selective serotonin reuptake inhibitors (SSRIs) in pregnancy. The majority of the panelists argued against SSRI use during pregnancy due to potential risks such as altered fetal brain development and congenital cardiac malformations.
However, leading medical organizations, including the American College of Obstetricians and Gynecologists (ACOG), countered that current data do not support a causal relationship between prenatal SSRI exposure and autism spectrum disorder. ACOG stated that SSRIs are safe in pregnancy and that most do not increase the risk for birth defects.
The panel highlighted the importance of examining data objectively and accounting for confounding factors such as maternal depression. Panelists, including Dr. Kay Roussos-Ross, emphasized the potential benefits of appropriately managed SSRI use during pregnancy, particularly for perinatal depression.
However, critics argue that the panel’s discussion was inconsistent with scientific evidence and clinical guidelines. They worry that the goal of this discussion may be to stigmatize the use of antidepressants during pregnancy and exaggerate the risk.
The FDA emphasizes its efforts to apply rigorous, evidence-based standards to ingredient safety and modernize regulatory oversight. The agency acknowledges the need for better communication between doctors and patients regarding the risks of SSRI use during pregnancy.
In conclusion, while there are valid concerns about the potential risks of SSRI use in pregnancy, it is essential to approach this topic with caution and consider multiple perspectives. Further research and education are needed to ensure that women receive accurate information about their treatment options during pregnancy.
Source: https://www.medscape.com/viewarticle/fda-panel-casts-doubt-safety-ssri-use-pregnancy-2025a1000jq9